Back to dashboard
CommercialCoverageMedium impact

08.00.99e, Belimumab (Benlysta®) for Intravenous Use

Independence Blue Cross·Rheumatology, Nephrology, Allergy & Immunology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

The Belimumab (Benlysta®) intravenous use policy has been reissued with an effective date of May 28, 2025. This is a pharmacy policy update for commercial plans, but specific changes are not detailed in the summary provided.

Action Required

Action needed
By May 28, 2025: Review the complete policy document at the provided URL to determine specific billing requirements for Belimumab (Benlysta®) intravenous administration. Update billing protocols and prior authorization requirements as specified in the full policy document.

Related policy hubs